Uchida Hajime, Sakamoto Seisuke, Yanagi Yusuke, Shimizu Seiichi, Fukuda Akinari, Ono Hiroshi, Miyazaki Osamu, Nosaka Shunsuke, Schlegel Andrea, Kasahara Mureo
Organ Transplantation Center, National Center for Child Health and Development, Setagaya-ku, Tokyo, Japan.
Division of Cardiology, National Center for Child Health and Development, Setagaya-ku, Tokyo, Japan.
Hepatol Res. 2023 Jun;53(6):540-555. doi: 10.1111/hepr.13882. Epub 2023 Feb 1.
To review the current institutional practice to treat patients with congenital extrahepatic portosystemic shunt (CEPS) and to determine the optimal strategy.
We retrospectively reviewed the records of 55 patients diagnosed with CEPS at our center between December 2008 and March 2022.
Among these 55 patients, 44 (80.0%) received treatment for CEPS at a median age of 4.7 years. The most common indication for treatment was cardiopulmonary complications (45.5%). Therapeutic intervention included shunt closure by endovascular techniques (50.0%) or surgery (40.9%), and liver transplantation (9.1%). A total of 11 were classified as short shunt types, and surgical ligation was performed in all to preserve the major vascular system and prevent complications (p < 0.001). Children who received a surgical ligation were more likely to develop complications after shunt closure (p = 0.02). Among seven patients with portopulmonary hypertension (POPH), one patient, who received a shunt ligation at <1 year-of-age, was only able to completely discontinue medication. Most other CEPS-related complications were completely resolved. Post-treatment complications, including thrombosis and symptoms of portal hypertension, were seen in 16 patients. After shunt closure, one patient was scheduled to undergo liver transplantation for progressive POPH and large residual hepatocellular adenoma. During follow-up, one patient without any treatment for CEPS developed POPH 16 years from the diagnosis.
Earlier therapeutic interventions should be strongly considered for patients with POPH related to CEPS. However, in view of the invasiveness and treatment complications, special attention should be paid to the management of patients with short shunt types.
回顾目前治疗先天性肝外门体分流(CEPS)患者的机构实践,并确定最佳策略。
我们回顾性分析了2008年12月至2022年3月期间在本中心诊断为CEPS的55例患者的记录。
在这55例患者中,44例(80.0%)接受了CEPS治疗,中位年龄为4.7岁。最常见的治疗指征是心肺并发症(45.5%)。治疗干预包括通过血管内技术(50.0%)或手术(40.9%)关闭分流,以及肝移植(9.1%)。共有11例被归类为短分流类型,均进行了手术结扎以保留主要血管系统并预防并发症(p<0.001)。接受手术结扎的儿童在分流关闭后更易发生并发症(p=0.02)。在7例肝肺综合征(POPH)患者中,1例在<1岁时接受分流结扎的患者仅能完全停用药物。大多数其他与CEPS相关的并发症完全得到解决。16例患者出现了包括血栓形成和门静脉高压症状在内的治疗后并发症。分流关闭后,1例患者因进行性POPH和巨大残留肝细胞腺瘤计划接受肝移植。在随访期间,1例未接受CEPS治疗的患者在诊断后16年发生了POPH。
对于与CEPS相关的POPH患者,应强烈考虑早期治疗干预。然而,鉴于其侵入性和治疗并发症,应特别关注短分流类型患者的管理。